Amgen plans to buy ChemoCentryx, a one-drug Bay Area biotech, for $3.7 billion

The deal could be a sign of a pick-up in mergers and acquisitions in the Bay Area's biotechnology space.

Source: bizjournals.com Health Care:Physician Practices headlines - August 4, 2022 Category: American Health Authors: Ron Leuty Source Type: news